Immune-related adverse event-myocarditis with marked ST-segment elevation requiring differentiation from COVID-19-induced myocarditis: a case report.
Kana FujitaYoshitaka OhashiYoshinori NagasawaTomoyuki OtaniKinta HatyakeyamaPublished in: European heart journal. Case reports (2024)
In irAEs, myocarditis is the most common and severe cardiac manifestation with a high mortality. Even at 20 weeks after the initial ICI treatment, irAE-myocarditis occurs and the clinical presentation may mimic ST-elevation myocardial infarction. The histopathological findings suggested the high possibility of irAE-myocarditis rather than COVID-19-induced myocarditis, but COVID-19 has possibly played a role in the development of late-onset irAE-myocarditis. This educational case implies the importance of immediate recognition of irAE even after stable ICI treatment.
Keyphrases
- coronavirus disease
- late onset
- sars cov
- st elevation myocardial infarction
- early onset
- high glucose
- drug induced
- percutaneous coronary intervention
- diabetic rats
- type diabetes
- emergency department
- cardiovascular disease
- combination therapy
- endothelial cells
- risk factors
- respiratory syndrome coronavirus
- atrial fibrillation
- adverse drug